Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05295589
Title Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

peritoneum cancer

fallopian tube cancer

ovarian serous carcinoma

ovarian endometrial cancer

ovarian cancer



Pegylated liposomal-doxorubicin

Copanlisib + Olaparib


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.